Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients

World Journal of Gastroenterology

Volumn 19, Issue 23, 2013, Pages 3573-3582

  Kodar, Kristel ^a,b   Izotova, Jelena ^a,b   Klaamas, Kersti ^a   Sergeyev, Boris ^a   Järvekülg, Lilian ^b   Kurtenkov, Oleg ^a  

^a NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

^b TALLINN UNIVERSITY OF TECHNOLOGY   (Estonia)

Author keywords

Anticarbohydrate antibodies; IgG glycosylation; Lectins; Stomach cancer; Survival; Thomsen Friedenreich antigen

Indexed keywords

AGGLUTININ; ANTI THOMSEN FRIEDENREICH GLYCOTOPE; CONCANAVALIN A; IMMUNOGLOBULIN G; PROTEIN G; SEPHAROSE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AFFINITY CHROMATOGRAPHY; AGED; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION; HUMAN; KAPLAN MEIER METHOD; LECTIN BINDING; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STOMACH CANCER;

EID: 84879156795     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i23.3573     Document Type: Article

References (43)

1. Hakomori S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 1989; 52: 257-331 [PMID: 2662714 DOI: 10.1016/S0065-230X(08)60215-8]
2. Springer GF. T and Tn, general carcinoma autoantigens. Science 1984; 224: 1198-1206 [PMID: 6729450 DOI: 10.1126/science. 6729450]
3. Springer GF, Desai PR, Spencer BD, Tegtmeyer H, Carlstedt SC, Scanlon EF. T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced breast carcinoma. Cancer Detect Prev 1995; 19: 374-380 [PMID: 7553680]
4. Vollmers HP, Brändlein S. Natural antibodies and cancer. J Autoimmun 2007; 29: 295-302 [PMID: 17826951 DOI: 10.1016/ j.jaut.2007.07.013]
5. Wandall HH, Blixt O, Tarp MA, Pedersen JW, Bennett EP, Mandel U, Ragupathi G, Livingston PO, Hollingsworth MA, Taylor-Papadimitriou J, Burchell J, Clausen H. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res 2010; 70: 1306-1313 [PMID: 20124478 DOI: 10.1158/0008-5472.CAN-09-2893]
6. Kanoh Y, Mashiko T, Danbara M, Takayama Y, Ohtani S, Egawa S, Baba S, Akahoshi T. Changes in serum IgG oligosaccharide chains with prostate cancer progression. Anticancer Res 2004; 24: 3135-3139 [PMID: 15510601]
7. Abd Hamid UM, Royle L, Saldova R, Radcliffe CM, Harvey DJ, Storr SJ, Pardo M, Antrobus R, Chapman CJ, Zitzmann N, Robertson JF, Dwek RA, Rudd PM. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology 2008; 18: 1105-1118 [PMID: 18818422 DOI: 10.1093/glycob/cwn095]
8. Kodar K, Kurtenkov O, Klaamas K. The Thomsen-Friedenreich antigen and alphaGal-specific human IgG glycoforms: concanavalin A reactivity and relation to survival of cancer patients. Immunol Invest 2009; 38: 704-717 [PMID: 19860583 DOI: 10.3109/08820130903147193]
9. Kodar K, Stadlmann J, Klaamas K, Sergeyev B, Kurtenkov O. Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconj J 2012; 29: 57-66 [PMID: 22179780 DOI: 10.1007/s10719-011-9364-z]
10. Bones J, Byrne JC, O'Donoghue N, McManus C, Scaife C, Boissin H, Nastase A, Rudd PM. Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. J Proteome Res 2011; 10: 1246-1265 [PMID: 21142185 DOI: 10.1021/pr101036b]
11. Springer GF, Desai PR, Tegtmeyer H, Spencer BD, Scanlon EF. Pancarcinoma T/Tn antigen detects human carcinoma long before biopsy does and its vaccine prevents breast carcinoma recurrence. Ann N Y Acad Sci 1993; 690: 355-357 [PMID: 8368754 DOI: 10.1111/j.1749-6632.1993.tb44029.x]
12. Springer GF. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med (Berl) 1997; 75: 594-602 [PMID: 9297627 DOI: 10.1007/ s001090050144]
13. Baldus SE, Zirbes TK, Hanisch FG, Kunze D, Shafizadeh ST, Nolden S, Mönig SP, Schneider PM, Karsten U, Thiele J, Hölscher AH, Dienes HP. Thomsen-Friedenreich antigen presents as a prognostic factor in colorectal carcinoma: A clinicopathologic study of 264 patients. Cancer 2000; 88: 1536-1543 [PMID: 10738210 DOI: 3.0.CO;]
14. Desai PR. Immunoreactive T and Tn antigens in malignancy: role in carcinoma diagnosis, prognosis, and immunotherapy. Transfus Med Rev 2000; 14: 312-325 [PMID: 11055076 DOI: 10.1053/tmrv.2000.16229]
15. Yu LG. The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression. Glycoconj J 2007; 24: 411-420 [PMID: 17457671 DOI: 10.1007/s10719-007-9034-3]
16. Schindlbeck C, Jeschke U, Schulze S, Karsten U, Janni W, Rack B, Krajewski S, Sommer H, Friese K. Prognostic impact of Thomsen-Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients. Breast Cancer Res Treat 2007; 101: 17-25 [PMID: 16807671 DOI: 10.1007/s10549-006-9271-3]
17. Glinsky VV, Glinsky GV, Rittenhouse-Olson K, Huflejt ME, Glinskii OV, Deutscher SL, Quinn TP. The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res 2001; 61: 4851-4857 [PMID: 11406562]
18. Heimburg J, Yan J, Morey S, Glinskii OV, Huxley VH, Wild L, Klick R, Roy R, Glinsky VV, Rittenhouse-Olson K. Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11. Neoplasia 2006; 8: 939-948 [PMID: 17132226 DOI: 10.1593/ neo.06493]
19. Springer GF, Desai PR, Ghazizadeh M, Tegtmeyer H. T/ Tn pancarcinoma autoantigens: fundamental, diagnostic, and prognostic aspects. Cancer Detect Prev 1995; 19: 173-182 [PMID: 7750105]
20. Kurtenkov O, Miljukhina L, Smorodin J, Klaamas K, Bovin N, Ellamaa M, Chuzmarov V. Natural IgM and IgG antibodies to Thomsen-Friedenreich (T) antigen in serum of patients with gastric cancer and blood donors--relation to Lewis (a, b) histo-blood group phenotype. Acta Oncol 1999; 38: 939-943 [PMID: 10606423 DOI: 10.1080/028418699432626]
21. Kurtenkov O, Klaamas K, Mensdorff-Pouilly S, Miljukhina L, Shljapnikova L, Chuzmarov V. Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival. Acta Oncol 2007; 46: 316-323 [PMID: 17450466 DOI: 10.1080/0284186060 1055441]
22. Smorodin EP, Kurtenkov OA, Sergeyev BL, Kodar KE, Chuzmarov VI, Afanasyev VP. Postoperative change of anti-Thomsen-Friedenreich and Tn IgG level: the follow-up study of gastrointestinal cancer patients. World J Gastroenterol 2008; 14: 4352-4358 [PMID: 18666325 DOI: 10.3748/wjg.14.4352]
23. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25: 21-50 [PMID: 17029568 DOI: 10.1146/annurev.immunol. 25.022106.141702]
24. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 2007; 44: 1524-1534 [PMID: 17045339 DOI: 10.1016/ j.molimm.2006.09.005]
25. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20: 471-478 [PMID: 18606225 DOI: 10.1016/j.coi.2008.06.007]
26. Gerçel-Taylor C, Bazzett LB, Taylor DD. Presence of aberrant tumor-reactive immunoglobulins in the circulation of patients with ovarian cancer. Gynecol Oncol 2001; 81: 71-76 [PMID: 11277653 DOI: 10.1006/gyno.2000.6102]
27. Sumar N, Bodman KB, Rademacher TW, Dwek RA, Williams P, Parekh RB, Edge J, Rook GA, Isenberg DA, Hay FC. Analysis of glycosylation changes in IgG using lectins. J Immunol Methods 1990; 131: 127-136 [PMID: 2199577 DOI: 10.1016/0022-1759(90)90242-N]
28. Miyamoto S. Clinical applications of glycomic approaches for the detection of cancer and other diseases. Curr Opin Mol Ther 2006; 8: 507-513 [PMID: 17243486]
29. Pasek M, Duk M, Podbielska M, Sokolik R, Szechiński J, Lisowska E, Krotkiewski H. Galactosylation of IgG from rheumatoid arthritis (RA) patients--changes during therapy. Glycoconj J 2006; 23: 463-471 [PMID: 17006638 DOI: 10.1007/ s10719-006-5409-0]
30. Stadlmann J, Weber A, Pabst M, Anderle H, Kunert R, Ehrlich HJ, Peter Schwarz H, Altmann F. A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics 2009; 9: 4143-4153 [PMID: 19688751]
31. Klaamas K, Kodar K, Kurtenkov O. An increased level of the Concanavalin A-positive IgG in the serum of patients with gastric cancer as evaluated by a lectin enzyme-linked immunosorbent assay (LELISA). Neoplasma 2008; 55: 143-150 [PMID: 18237253]
32. Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffiss JM. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun 1988; 56: 1730-1737 [PMID: 3290105]
33. Kurtenkov O, Klaamas K, Miljukhina L. The lower level of natural anti-Thomsen-Friedenreich antigen (TFA) agglutinins in sera of patients with gastric cancer related to ABO(H) blood-group phenotype. Int J Cancer 1995; 60: 781-785 [PMID: 7896445 DOI: 10.1002/ijc.2910600609]
34. Burton DR, Dwek RA. Immunology. Sugar determines antibody activity. Science 2006; 313: 627-628 [PMID: 16888131 DOI: 10.1126/science.1131712]
35. Jefferis R. A sugar switch for anti-inflammatory antibodies. Nat Biotechnol 2006; 24: 1230-1231 [PMID: 17033662 DOI: 10.1038/nbt1006-1230]
36. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313: 670-673 [PMID: 16888140 DOI: 10.1126/science. 1129594]
37. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320: 373-376 [PMID: 18420934 DOI: 10.1126/science.1154315]
38. Schreiber H, Wu TH, Nachman J, Rowley DA. Immunological enhancement of primary tumor development and its prevention. Semin Cancer Biol 2000; 10: 351-357 [PMID: 11100883 DOI: 10.1006/scbi.2000.0331]
39. Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets 2010; 11: 1133-1146 [PMID: 20545607 DOI: 10.2174/138945010792006799]
40. Satoh M, Iida S, Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 2006; 6: 1161-1173 [PMID: 17049014 DOI: 10.1517/14712598.6.11.1161]
41. Iida S, Kuni-Kamochi R, Mori K, Misaka H, Inoue M, Okazaki A, Shitara K, Satoh M. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer 2009; 9: 58 [PMID: 19226457 DOI: 10.1186/1471-2407-9-58]
42. Mizushima T, Yagi H, Takemoto E, Shibata-Koyama M, Isoda Y, Iida S, Masuda K, Satoh M, Kato K. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells 2011; 16: 1071-1080 [PMID: 22023369 DOI: 10.1111/j.1365-2443.2011.01552.x]
43. Stadlmann J, Pabst M, Altmann F. Analytical and Functional Aspects of Antibody Sialylation. J Clin Immunol 2010; Epub ahead of print [PMID: 20390325 DOI: 10.1007/ s10875-010-9409-2]